Revenue surged in Q4 due to the ES-Medical acquisition, but full-year sales declined after divestments. Operating losses narrowed sharply, cash position improved, and the company remains focused on acquisitions and cost discipline.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.